International Journal of Gerontology
Volume 3, Issue 3 , Pages 163-169, September 2009

Clinical Genomics Identifies the Expression of Human Ovarian Carcinoma

  • Meng-Hsiun Tsai

      Affiliations

    • Department of Management Information Systems and Institute of Bioinformatics, National Chung Hsing University, Taichung, Taiwan
    • ,
  • Steve G. Huang

      Affiliations

    • Institute of Nanotechnology, National Chiao Tung University, Hsinchu, Taiwan
    • ,
  • Shyh-Chang Tsaur

      Affiliations

    • Department of Computer Science and Information Engineering, Asia University, Taichung, Taiwan
    • ,
  • Yao-Ching Hung

      Affiliations

    • Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, China Medical University and Hospital, Taichung, Taiwan
    • ,
  • Sheng-Hsiung Chiu

      Affiliations

    • Troilus Bio-technology Co. Ltd, Taichung, Taiwan
    • ,
  • Chi-Wei Wang

      Affiliations

    • Department of Computer Science and Information Engineering, Asia University, Taichung, Taiwan
    • Department of Internal Medicine, Ben Tang Cheng Ching Hospital, Taichung, Taiwan
    • Corresponding Author InformationCorrespondence to: Dr Chi-Wei Wang, Department of Internal Medicine, Ben Tang Cheng Ching Hospital, 718, Zhongzheng Road, Wufeng Township, Taichung County 413, Taiwan

Accepted 8 March 2009.

Article Outline

Summary 

Background

Human ovarian carcinoma is a silent killer. Most patients with human ovarian carcinoma are diagnosed in the advanced stages. Currently, no effective means of early detection are available. Identifying genes that distinguish early cancers from normal tissue may provide insight to the initiation and progression of ovarian cancer.

Methods

A large-scale gene expression profiling using 9,600 genes-complementary DNA array to study ovarian tumors was conducted. We analyzed 13 benign tumors, 22 invasive cancers (seven stage I and 15 stage III), and 16 normal ovaries. Cluster analysis revealed two major groups: the early-stage cluster that included 13 benign tumors and seven stage I cancers; and the late-stage cluster that included all stage III cancers.

Results

There were 433 upregulated and 60 downregulated genes from the early-stage cluster, and 395 upregulated and 101 downregulated genes from the late-stage cluster. These genes showed altered functions for tumor/cancers, functions such as cell growth, cell cycle control, differentiation, signaling, apoptosis, ion transport, and morphogenesis. Of most interest is the downregulation of nuclear receptor proteins. Differentially expressed genes between early-stage cluster and late-stage clusters were identified. We found 90 genes preferentially overly expressed and 165 genes relatively downregulated at late-stage cancers. The advanced cancer appears differently from early-stage cancer in cell growth, cell adhesion, hormone activity, morphology, and cell–cell signaling compared with benign or early-stage cancer. Of particular interest are enzymes corresponding to pteridine biosynthesis, reported for the first time in this study. Real-time reverse transcription polymerase chain reaction showed that GCH1, KRT18, H3F3A, and MYBL2 were overly expressed in all cancer tissues, while MDFI, ARP3BETA, COL16A1, and MLN discriminated late-stage from early-stage cancers.

Conclusion

The microarray provides valuable resources for comparing expression profiles of cancers at various stages and helps research the diagnosis and mechanism of ovarian cancer.

Key Words:  borderline malignancy , expression profile , microarray , ovarian tumor , real-time reverse transcription polymerase chain reaction

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Jemal A , Thomas A , Murray T , et al.   Cancer statistics, 2002 . CA Cancer J Clin . 2002;52:23–47
  2. Yamamoto S , Konishi I , Mandai M , et al.   Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels . Br J Cancer . 1997;76:1221–1227
  3. Schena M , Shalon D , Davis RW , et al.   Quantitative monitoring of gene expression patterns with a complementary DNA microarray . Science . 1995;270:467–470
  4. Alizadeh AA , Eisen MB , Davis RE , et al.   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling . Nature . 2000;403:503–511
  5. DeRisi J , Penland L , Brown PO , et al.   Use of a cDNA micro-array to analyse gene expression patterns in human cancer . Nat Genet . 1996;14:457–460
  6. Schummer M , Ng WV , Bumgarner RE , et al.   Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas . Gene . 1999;238:375–385
  7. Wang K , Gan L , Jeffery E , et al.   Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray . Gene . 1999;229:101–108
  8. Ismail RS , Baldwin RL , Fang J , et al.   Differential gene expression between normal and tumor-derived ovarian epithelial cells . Cancer Res . 2000;60:6744–6749
  9. Martoglio AM , Tom BD , Starkey M , et al.   Changes in tumorigenesis-and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays . Mol Med . 2000;6:750–765
  10. Ono K , Tanaka T , Tsunoda T , et al.   Identification by cDNA microarray of genes involved in ovarian carcinogenesis . Cancer Res . 2000;60:5007–5011
  11. Welsh JB , Zarrinkar PP , Sapinoso LM , et al.   Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer . Proc Natl Acad Sci USA . 2001;98:1176–1181
  12. Pecorelli S , Odicino F , Maisonneuve P , et al.   FIGO annual report on the results of treatment in gynaecological cancer: carcinoma of the ovary . J Epidemiol Biostat . 1998;3:75–102
  13. Brazma A , Hingamp P , Quackenbush J , et al.   Minimum information about a microarray experiment (MIAME)-toward standards for microarray data . Nat Genet . 2001;29:365–371
  14. Cleveland WS . Robust locally weighted regression and smoothing scatter plots . J Am Stat Assoc . 1979;74:829–836
  15. Neyns B , Katesuwanasing  , Vermeij J , et al.   Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium . Oncogene . 1996;12:1247–1257
  16. Morrison TB , Weis JJ , Wittwer CT . Quantification of lowcopy transcripts by continuous SYBR Green I monitoring during amplification . Biotechniques . 1998;24:954–962
  17. Heintz AP , Odicino F , Maisonneuve P , et al.   Carcinoma of the ovary . J Epidemiol Biostat . 2001;6:107–138
  18. Holmes D , Brynjolfsson J , Brett P , et al.   No evidence for a susceptibility locus predisposing to manic depression in the region of the dopamine (D2) receptor gene . Br J Psychiatry . 1991;158:635–641
  19. Boerboom D , Pilon N , Behdjani R , et al.   Expression and regulation of transcripts encoding two members of the NR5A nuclear receptor subfamily of orphan nuclear receptors, steroidogenic factor-1 and NR5A2, in equine ovarian cells during the ovulatory process . Endocrinology . 2000;141:4647–4656
  20. Laflamme C , Filion C , Bridge JA , et al.   The homeotic protein Six3 is a coactivator of the nuclear receptor NOR-1 and a corepressor of the fusion protein EWS/NOR-1 in human extraskeletal myxoid chondrosarcomas . Cancer Res . 2003;63:449–454
  21. Jenkins DC , Charles IG , Thomsen LL , et al.   Roles of nitric oxide in tumor growth . Proc Natl Acad Sci USA . 1995;92:4392–4396

PII: S1873-9598(09)70042-0

doi:10.1016/S1873-9598(09)70042-0

International Journal of Gerontology
Volume 3, Issue 3 , Pages 163-169, September 2009

Article Tools